First you’ll need to log back into 23andMe, if you can remember your details that is. Then you can submit the deletion ...

The global generic oncology drugs market is projected to grow at a 6% CAGR from 2022 to 2028, reaching over USD 34.8 billion ...

Analysts expect the partners’ first-mover advantage, clinical data and existing presence in lung disease to translate into ...

GSK announces positive phase III results from ANCHOR trials for depemokimab in chronic rhinosinusitis with nasal polyps: London, UK Tuesday, October 15, 2024, 10:00 Hrs [IST] GSK ...

Locally advanced cervical cancer remains a substantial source of mortality, particularly in low-resource settings.1 ...

GSK plc (LSE/NYSE: GSK) has released new data from the AReSVi-006 Phase III trial, demonstrating the efficacy and safety of ...

GSK announced positive results from two phase 3 clinical trials evaluating its experimental drug, depemokimab, for chronic rhinosinusitis with nasal polyps affecting 4% of the population.

Antiviral Drugs MarketThe antiviral drugs market is anticipated to experience significant growth, flourishing at an average ...

The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.

Artificial intelligence chatbots cannot be relied on to give accurate, safe or even clear advice about medication, according ...

New data to be shared on GSK’s RSV vaccine across different age groups of patients at increased risk • Efficacy data for gepotidacin in ...

GSK announced another batch of positive data from its respiratory program with the investigational drug depemokimab, this ...